• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 27, 2015

View Archived Issues

NASH flash: Emricasan data boost Conatus; Genfit falls on fuzzy findings

In January, investors in Conatus Pharmaceuticals Inc. showed their displeasure with early stage pharmacokinetic and pharmacodynamic findings on the use of emricasan in patients with impaired liver function by sending the company's shares (NASDAQ:CNAT) into a 40 percent freefall. Read More

Innate Pharma stock drops on mixed DSMB recommendation

DUBLIN – Shares in Innate Pharma SA fell 14 percent Thursday on news that a data safety and monitoring board (DSMB) called a halt to one treatment arm of a phase II trial in acute myeloid leukemia (AML) testing lirilumab (IPH2102, BMS-986015), an immunotherapeutic antibody that targets inhibitory killer-cell immunoglobulin-like receptors (KIRs) expressed by natural killer (NK) cells. Read More

Clinical, preclinical progress reported on Ebola vaccines

It's been a fruitful week for Ebola vaccines, with progress reported ranging from phase III to the preclinical arena. Clinically, the first phase III efficacy trial of an Ebola vaccine got under way in Guinea this week. VSV-EBOV, which Merck & Co. Inc. licensed from Newlink Genetics Corp., is being tested in a two-step trial. Read More

Vical adds fungus-fighter from Astellas to portfolio via in-licensing deal

Vical Inc. is moving to expand its infectious disease portfolio by in-licensing a trial-ready antifungal from Astellas Pharma Inc. that could complement a DNA-based cytomegalovirus (CMV) vaccine on which the companies already collaborate. Read More

Licensing under Brulotte decision is at risk in March SCOTUS hearing

The U.S. Supreme Court will hear arguments March 31 in the case of Kimble v. Marvel, a case that tackles the issue of whether royalties necessarily expire when the underlying patent expires. Read More

Financings

Novavax Inc., of Gaithersburg, Md., priced an underwritten public offering of about 24 million shares of common stock at a price to the public of $7.25 per share for gross proceeds of about $175 million. Read More

Other news to note

Aduro Biotech Inc., of Berkeley, Calif., landed an orphan drug designation for CRS-207, its experimental treatment for patients with malignant pleural mesothelioma who have not received prior therapy and are not eligible for surgical resection. Read More

Stock movers

Read More

In the clinic

Transition Therapeutics Inc., of Toronto, reported results from two phase I studies of neuropsychiatric drug candidate ELND005. Read More

Pharma: Other news to note

Helsinn Group, of Lugano, Switzerland, and Mundipharma International Corp. Ltd., of Singapore, said they entered a distribution and license agreement for the exclusive rights to anamorelin in Mainland China, Hong Kong and Macao. Read More

Pharma: In the clinic

Sanofi SA, of Paris, said its Genzyme unit disclosed the publication of results from the phase III ENCORE study exploring Cerdelga (eliglustat) as a maintenance therapy suitable for adult patients who had reached pre-specific treatment goals on enzyme replacement therapy (ERT) in the online issue of The Lancet. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Neuronata-R

    Corestemchemon preps US BLA filing for stem cell ALS therapy

    BioWorld Asia
    Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe